Oukejian Biopharmaceutical Technology

Oculgen's business model is centered on the complete lifecycle of drug development, from early-stage target discovery and independent research to the commercialization of its products. The company's revenue generation is anticipated through the successful development and marketing of its proprietary drug pipeline. The firm operates in the global ophthalmology market, with a mission to address unmet clinical needs for patients in China, Asia, and worldwide by providing advanced and affordable treatments. Headquartered in Shenzhen with a research and development center in Zhuhai, Oculgen targets major fundus diseases that are leading causes of blindness.

The company's product pipeline includes several multi-specific and monoclonal antibody drugs. Its core product, OCUL101, is a first-in-class, dual-target antibody fusion protein. It is being developed to treat neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and geographic atrophy (GA). OCUL101 received clinical trial approvals from both the U.S. FDA and China's CDE, with the first-in-human I/II phase clinical trial initiated in March 2025. Other pipeline candidates include OCUL201 and OCUL301, which target conditions such as diabetic retinopathy (DR) and polypoidal choroidal vasculopathy (PCV). In January 2025, Oculgen secured over 100 million RMB in a Series A financing round to advance the clinical trials of its drug candidates in both China and the US.